Safety and efficacy of ertugliflozin plus sitagliptin versus either treatment alone in subjects with type 2 diabetes inadequately controlled with metformin: the VERTIS FACTORIAL trial Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Pratley, R., Eldor, R., Golm, G., Huyck, S., Qiu, Y., Sunga, S., Johnson, J., Terra, S., Mancuso, J., Engel, S. S., Lauring, B.

funding text

  • Supported by: Merck & Co, Inc. in collaboration with Pfizer

authors

Publication Date

  • August 1, 2016

webpage

published in

category

start page

  • S347

end page

  • S347

volume

  • 59

WoS Citations

  • 0

WoS References

  • 0